Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation, has signed an exclusive license agreement with Wayne State University in Detroit, MI, for IP covering newly discovered biomarkers of ovarian cancer. The agreement grants Arrayit exclusive worldwide rights to develop and commercialize a novel microarray-based diagnostic test using biomarkers developed by Wayne State researchers. The test aims to effectively screen for early-stage ovarian cancer in women who are not yet symptomatic. According to the National Cancer Institute, ovarian cancer is the fourth leading cause of death among U.S. women, yet no adequate screening or diagnostic test for early-stage detection exists. As a result, most ovarian cancers are diagnosed only when later stage symptoms manifest and the disease has metastasized to other parts of the body. In the near future, Arrayit plans to file a premarket approval application for its pre-symptomatic ovarian cancer diagnostic test with the U.S. Food and Drug Administration.
Source: Clinical Lab Products